Zimmer® Announces 1000th Implantation of its Zimmer Natural Nail™ Cephalomedullary Nail
WARSAW, Ind., Oct 13, 2010 /PRNewswire via COMTEX News Network/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal care, today announced the one thousandth implantation of its Zimmer Natural Nail Cephalomedullary Nail in the United States since the product release in April 2010. The Zimmer Natural Nail system features an innovative design focused on restoring patients' original anatomy.
The Zimmer Natural Nail Cephalomedullary Nail is designed to help address fractures of the femur, especially intertrochanteric and subtrochanteric fractures. The System is a next-generation line of intramedullary nails, screws and instruments designed to provide surgeons with an intuitive and easy-to-use system for long bone fixation.
"The rapid success of our Cephalomedullary Nail since its introduction earlier this year is testament to its truly innovative design," said Jeffrey Paulsen, President, Zimmer Global Businesses. "The nail enables surgeons to help restore the natural anatomies of patients of all shapes and sizes."
Both the long and short Cephalomedullary Nails have anatomical bows that help restore the shape of the femur to its natural, pre-injury state. The System utilizes Zimmer's patented StabliZe Technology and optimized screw locations to help better link the nail to bone. Screws are placed throughout the implant to further secure it and maintain length and alignment during the healing process. These features help surgeons to achieve stable fixation even in osteoporotic bone. Color-coded instrumentation makes it simple to match nails with their corresponding guides. A wide range of widths, lengths and center-column-diaphyseal (CCD) angles is available to match implants to the individual anatomy of the patient.
Zimmer has initiated a prospective, multi-center, post-market clinical study to monitor and document the outcomes of patients receiving either the short or long Cephalomedullary Nail in intertrochanteric and subtrochanteric proximal femoral fractures.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2009 sales were approximately $4.1 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
We routinely post important information for investors on our website, www.zimmer.com, in the "Investor Relations" section. We intend to use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.